|
|
Vaccine Detail
|
VXA-CoV2-1 |
| Vaccine Information |
- Vaccine Name: VXA-CoV2-1
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Vaxart
- Vaccine Ontology ID: VO_0005196
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Oral
|
| Host Response |
|
Hamster Response
- Immune Response: Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity. (Johnson et al., 2022)
- Efficacy: Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease. (Johnson et al., 2022)
|
| References |
Johnson et al., 2022: Susan Johnson 1, Clarissa I Martinez 1, Sarah N Tedjakusuma 1, Nadine Peinovich 1, Emery G Dora 1, Sharla M Birch 2, Adriana E Kajon 2, Adam D Werts 2, Sean N Tucker 1. Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model. . 2022; ; . [PubMed: 34758086].
|
|
